HOME >> MEDICINE >> NEWS
Drug-eluting stents outperform radiation treatment for coronary restenosis in bare metal stents

In the first published trial of its kind, a multi-center clinical study has shown that drug-eluting stents outperform the current "gold standard" radiation treatment in managing coronary restenosis and in preventing further clogging of coronary arteries.

Results of the TAXUS Express stent trial led by Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia were published in the March 15 issue of the Journal of the American Medical Association. The study results were also presented March 12 at the American College of Cardiology's annual scientific meeting in Atlanta.

The trial studied 396 patients whose bare metal stents had become clogged with scar tissue, a common complication called restenosis. About half of the patients received paclitaxel-eluting stents, while the other half received vascular brachytherapy, which delivers radiation to the inside of the artery via a catheter. Vascular brachytherapy is currently the only FDA-approved treatment for restenosis after bare metal stent implantation. Paclitaxel is a drug that inhibits cell migration and prevents restenosis. The TAXUS Express stent is made by Boston Scientific Corp.

After 9 months, the trial showed that the paclitaxel-eluting stents reduced by 40 percent the number of patients needing additional procedures to clear the artery, compared to vascular brachytherapy. Angiographic measurements in both groups showed that patients who had drug-eluting stents experienced less than half as much restenosis (14.5 percent) as those who had brachytherapy (31.2 percent).

The trial also showed that the benefits of paclitaxel-stenting were achieved without compromising safety. Paclitaxel stents reduced major cardiac events from 20.1 percent in the brachytherapy group to 11.5 percent. The two treatments had similar rates of cardiac death or myocardial infarction (5.2 percent for brachytherapy and 3.7 percent for stenting) and thrombosis in the stented artery
'"/>

Contact: Craig LeMoult
cel2113@columbia.edu
212-305-0820
Columbia University Medical Center
12-Mar-2006


Page: 1 2

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. Drug-eluting and absorbable stents push interventional frontiers
3. Drug-eluting stents may cause allergic reactions
4. Drug-eluting stents successfully treat vein-graft disease
5. SCAI news: Drug-eluting stents prove mettle in heart attack patients
6. New biodegradable magnesium stents for coronary arteries
7. Bare-metal stents are better for some heart patients
8. Off-label and untested use of drug-coated stents appears widespread
9. Studies highlight real world use, safety of drug-eluting stents
10. Jefferson scientists find that drug-eluting stents are disappointing in bypass grafts -- sometimes
11. SCAI issues clinical alert on drug-eluting stents and late thrombosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... ... November 14, 2019 , ... With Giving Tuesday on Dec. ... businesses and organizations about the benefits of supporting local hospitalized veterans throughout Maryland. ... millions of people to give, collaborate and celebrate generosity before the holidays, and ...
(Date:11/14/2019)... ... , ... EMulate Therapeutics, Inc., a clinical-stage therapeutic device company ... 5 poster presentations related to its medical devices for treating adult and pediatric ... Phoenix, beginning on November 20 . , Two posters will be ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... Administration (FDA) has granted acceptance to file status of its application for the ... in the disease neurofibromatosis type one (NF1). The FDA’s acceptance of the application ...
(Date:11/12/2019)... ... , ... AI for preventable harm analytics leader Jvion today announced that Jvion ... the Potential of AI”, which provides a “tip of the spear” analysis of the ... enough clients to complete a full KLAS analysis, Jvion was featured as having “by ...
(Date:11/12/2019)... TORONTO (PRWEB) , ... November 12, 2019 , ... ... of a clinical study. With increasing site activation cycle times, extended contract negotiations ... study start-up is an area of clinical operations that’s ripe for improvement. Following ...
Breaking Medicine News(10 mins):
(Date:11/11/2019)... ... November 11, 2019 , ... Oak Street Health , a network of ... new centers in Greensboro and Charlotte, with an additional center in Charlotte under development. ... different model of care that emphasizes quality of care rather than quantity of services. ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... mutual agreement to facilitate the coordination and implementation of joint projects for ... medicinal products. These undertakings will empower biomedical professionals to leverage their roles ...
(Date:11/11/2019)... (PRWEB) , ... November 10, 2019 , ... ... rebranding alongside a redesign of its website , which features over 600 ... from the brand's 35+ year commitment to providing high-quality health and wellness products, ...
Breaking Medicine Technology:
Cached News: